Respiratory Syncytial Virus (RSV) Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Respiratory syncytial virus (RSV) infection infects the lungs and breathing passages. RSV commonly causes bronchiolitis (inflammation of the small airways in the lung) and pneumonia in children less than one year of age.
The Respiratory Syncytial Virus pipeline market research report provides comprehensive information on the therapeutics under development for Respiratory Syncytial Virus, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Respiratory Syncytial Virus and features dormant and discontinued projects.
Respiratory Syncytial Virus Pipeline Products Market Segmentation by Targets
The key targets in the Respiratory Syncytial Virus pipeline products market are Respiratory Syncytial Virus Fusion Protein, Respiratory Syncytial Virus Attachment Glycoprotein, Respiratory Syncytial Virus RNA Directed RNA Polymerase L, Nucleocapsid Protein, Pulmonary Surfactant Associated Protein D, Respiratory Syncytial Virus Nucleoprotein, Toll Like Receptor 4, ATP Dependent RNA Helicase DDX3X, Complement C1q Subcomponent, Envelope Protein M, and others.
Respiratory Syncytial Virus Pipeline Products Market Analysis by Targets
For more target insights into the Respiratory Syncytial Virus pipeline products market, download a free report sample
Respiratory Syncytial Virus Pipeline Products Market Segmentation by Mechanisms of Action
The key mechanisms of action in the Respiratory Syncytial Virus pipeline products market are Respiratory Syncytial Virus Fusion Protein Inhibitor, Respiratory Syncytial Virus Attachment Glycoprotein Inhibitor, Respiratory Syncytial Virus RNA Directed RNA Polymerase L Inhibitor, Pulmonary Surfactant Associated Protein D Replacement, ATP Dependent RNA Helicase DDX3X Inhibitor, Complement C1q Subcomponent Inhibitor, Envelope Protein M Inhibitor, Exportin 1 Inhibitor, Fatty Acid Synthase Inhibitor, Glucocorticoid Receptor Agonist, and others.
Respiratory Syncytial Virus Pipeline Products Market Analysis by Mechanisms of Action
For more mechanisms of action insights into the Respiratory Syncytial Virus pipeline products market, download a free report sample
Respiratory Syncytial Virus Pipeline Products Market Segmentation by Routes of Administration
The key routes of administration in the RSV pipeline products market are intramuscular, nasal, oral, intravenous, inhalational, parenteral, intradermal, and intrapulmonary.
Respiratory Syncytial Virus Pipeline Products Market Analysis by Routes of Administration
For more routes of administration insights into the Respiratory Syncytial Virus pipeline products market, download a free report sample
Respiratory Syncytial Virus Pipeline Products Market Segmentation by Molecule Types
The key molecule types in the Respiratory Syncytial Virus pipeline products market are small molecule, subunit vaccine, monoclonal antibody, live attenuated vaccine, recombinant vector vaccine, mRNA vaccine, vaccine, recombinant protein, peptide, antisense RNAi oligonucleotide, and others.
Respiratory Syncytial Virus Pipeline Products Market Analysis by Molecule Types
For more molecule type insights into the Respiratory Syncytial Virus pipeline products market, download a free report sample
RSV Pipeline Products Market - Competitive Landscape
Some of the leading companies in the RSV pipeline products market are Johnson & Johnson, Merck & Co Inc, Shanghai Ark Biopharmaceutical Co Ltd, AstraZeneca Plc, Moderna Inc, Pfizer Inc, Sanofi, Enanta Pharmaceuticals Inc, GSK plc, and TechnoVax Inc.
Respiratory Syncytial Virus Pipeline Products Market Analysis by Companies
To know more about the leading players in the Respiratory Syncytial Virus pipeline products market, download a free report sample
Respiratory Syncytial Virus Pipeline Products Market Report Overview
Key Targets | Respiratory Syncytial Virus Fusion Protein, Respiratory Syncytial Virus Attachment Glycoprotein, Respiratory Syncytial Virus RNA Directed RNA Polymerase L, Nucleocapsid Protein, Pulmonary Surfactant Associated Protein D, Respiratory Syncytial Virus Nucleoprotein, Toll Like Receptor 4, ATP Dependent RNA Helicase DDX3X, Complement C1q Subcomponent, Envelope Protein M, and Others |
Key Mechanisms of Action | Respiratory Syncytial Virus Fusion Protein Inhibitor, Respiratory Syncytial Virus Attachment Glycoprotein Inhibitor, Respiratory Syncytial Virus RNA Directed RNA Polymerase L Inhibitor, Pulmonary Surfactant Associated Protein D Replacement, ATP Dependent RNA Helicase DDX3X Inhibitor, Complement C1q Subcomponent Inhibitor, Envelope Protein M Inhibitor, Exportin 1 Inhibitor, Fatty Acid Synthase Inhibitor, Glucocorticoid Receptor Agonist, and Others |
Key Routes of Administration | Intramuscular, Nasal, Oral, Intravenous, Inhalational, Parenteral, Intradermal, and Intrapulmonary |
Key Molecule Type | Small Molecule, Subunit Vaccine, Monoclonal Antibody, Live Attenuated Vaccine, Recombinant Vector Vaccine, mRNA Vaccine, Vaccine, Recombinant Protein, Peptide, Antisense RNAi Oligonucleotide, and Others |
Leading Companies | Johnson & Johnson, Merck & Co Inc, Shanghai Ark Biopharmaceutical Co Ltd, AstraZeneca Plc, Moderna Inc, Pfizer Inc, Sanofi, Enanta Pharmaceuticals Inc, GSK plc, and TechnoVax Inc |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Respiratory Syncytial Virus (RSV) Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Respiratory Syncytial Virus (RSV) Infections (Infectious Disease)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Respiratory Syncytial Virus (RSV) Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Abivax SA
ADMA Biologics Inc
Advac LLC
Advagene Biopharma Co Ltd
AIM Vaccine Co Ltd
Airway Therapeutics Inc
AlloVir Inc
Anima Biotech Inc
Aposense Ltd
Aridis Pharmaceuticals Inc
Artificial Cell Technologies Inc
AstraZeneca Plc
Atea Pharmaceuticals Inc
Atriva Therapeutics GmbH
Auro Vaccines LLC
AVM Biotechnology LLC
Bavarian Nordic AS
Beijing Advaccine Biotechnology Company Ltd
BioComo Inc
Biological E Ltd
Blue Lake Biotechnology Inc
BlueWillow Biologics Inc
BravoVax Co Ltd
Calder Biosciences Inc
Celestial Therapeutics Inc
Changchun Bcht Biotechnology Co Ltd
Chengdu Aoda Biotechnology Co Ltd
Chongqing Zhifei Biological Products Co Ltd
Cidara Therapeutics Inc
Clover Biopharmaceuticals Ltd
Codagenix Inc
ConserV Bioscience Ltd
Curevac NV
CyanVac LLC
Daiichi Sankyo Co Ltd
Enanta Pharmaceuticals Inc
Enyo Pharma SA
Esperovax Inc
Eucure (Beijing) Biopharma Co Ltd
Exopharm Ltd
F. Hoffmann-La Roche Ltd
Gilead Sciences Inc
GSK plc
HanaVax Inc
Heartland Vaccines LLC
iBio Inc
Icosavax Inc
IDBiologics Inc
ILiAD Biotechnologies LLC
Immunwork Inc
Imophoron Ltd
IMV Inc
Inhalon Biopharma Inc
Inovio Pharmaceuticals Inc
Intravacc BV
Johnson & Johnson
KARE Biosciences Inc
Karyopharm Therapeutics Inc
Kidswell Bio Corp
Mapp Biopharmaceutical Inc
Meissa Vaccines Inc
Merck & Co Inc
MicroQuin Ltd
Moderna Inc
Navigen Inc
NeuClone Pty Ltd
Neuracle Science Co Ltd
Novavax Inc
Oita University Institute of Advanced Medicine Inc
Pfizer Inc
Pinetree Therapeutics Inc
Pneumagen Ltd
Poolbeg Pharma Plc
Prime Vector Technologies GmbH
Primmune Therapeutics Inc
Prosit Sole Biotechnology (Beijing) Co Ltd
ReAlta Life Sciences Inc
Revelation Biosciences Inc
Riboscience LLC
Romark Laboratories LC
Ruiyang (Suzhou) Biotechnology Co Ltd
Sagimet Biosciences Inc
Sanofi.
Sciwind Biosciences Co Ltd
Shandong Danhong Pharmaceutical Co Ltd
Shanghai Ark Biopharmaceutical Co Ltd
Shionogi & Co Ltd
Sigmovir Biosystems Inc
Signia Therapeutics
SK Bioscience Ltd
Taisho Pharmaceutical Holdings Co Ltd
TechnoVax Inc
Trimunocor Ltd
TrippBio Inc
Uvax Bio LLC
Vault Pharma Inc
Vaxart Inc
Vaxxel SAS
Vicebio Ltd
Vir Biotechnology Inc
Viramatix Sdn Bhd
Viravaxx AG
Virometix AG
Visterra Inc
VLP Biotech Inc
X4 Pharmaceuticals Inc
XBiotech Inc
Zhuhai Trinomab Biotechnology Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the Respiratory Syncytial Virus pipeline products market?
The key targets in the Respiratory Syncytial Virus pipeline products market are Respiratory Syncytial Virus Fusion Protein, Respiratory Syncytial Virus Attachment Glycoprotein, Respiratory Syncytial Virus RNA Directed RNA Polymerase L, Nucleocapsid Protein, Pulmonary Surfactant Associated Protein D, Respiratory Syncytial Virus Nucleoprotein, Toll Like Receptor 4, ATP Dependent RNA Helicase DDX3X, Complement C1q Subcomponent, Envelope Protein M, and others.
-
What are the key mechanisms of action in the Respiratory Syncytial Virus pipeline products market?
The key mechanisms of action in the Respiratory Syncytial Virus pipeline products market are Respiratory Syncytial Virus Fusion Protein Inhibitor, Respiratory Syncytial Virus Attachment Glycoprotein Inhibitor, Respiratory Syncytial Virus RNA Directed RNA Polymerase L Inhibitor, Pulmonary Surfactant Associated Protein D Replacement, ATP Dependent RNA Helicase DDX3X Inhibitor, Complement C1q Subcomponent Inhibitor, Envelope Protein M Inhibitor, Exportin 1 Inhibitor, Fatty Acid Synthase Inhibitor, Glucocorticoid Receptor Agonist, and others.
-
What are the key routes of administration in the Respiratory Syncytial Virus pipeline products market?
The key routes of administration in the Respiratory Syncytial Virus pipeline products market are intramuscular, nasal, oral, intravenous, inhalational, parenteral, intradermal, and intrapulmonary.
-
What are the key molecule types in the Respiratory Syncytial Virus pipeline products market?
The key molecule types in the Respiratory Syncytial Virus pipeline products market are small molecule, subunit vaccine, monoclonal antibody, live attenuated vaccine, recombinant vector vaccine, mRNA vaccine, vaccine, recombinant protein, peptide, antisense RNAi oligonucleotide, and others.
-
Which are the leading companies in the RSV pipeline products market?
Some of the leading companies in the RSV pipeline products market are Johnson & Johnson, Merck & Co Inc, Shanghai Ark Biopharmaceutical Co Ltd, AstraZeneca Plc, Moderna Inc, Pfizer Inc, Sanofi, Enanta Pharmaceuticals Inc, GSK plc, and TechnoVax Inc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.